Results 51 to 60 of about 785,669 (310)
Supplemental data Figure 1 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against ...
Steven Duniho (14973184) +11 more
core +1 more source
Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson +2 more
wiley +1 more source
The Humanization and Maturation of an Anti-PrPc Antibody
The cellular prion protein (PrPc) is a cell surface glycoprotein that is highly expressed in a variety of cancer tissues in addition to the nervous system, and its elevated expression is correlated to poor prognosis in many cancer patients.
Cheng Zhang +9 more
doaj +1 more source
New targeted treatments for cutaneous T-cell Lymphomas
Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath)
Martine Bagot
doaj +1 more source
Supplemental data Figure 3 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against ...
Steven Duniho (14973184) +11 more
core +1 more source
Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui +10 more
wiley +1 more source
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. [PDF]
Therapeutic monoclonal antibodies (mAbs) such as the superagonistic, CD28-specific antibody TGN1412, or OKT3, an anti-CD3 mAb, can cause severe adverse events including cytokine release syndrome.
Sabrina Weißmüller +7 more
doaj +1 more source
Supplemental data Figure 4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against ...
Steven Duniho (14973184) +11 more
core +1 more source
Personalized targeting of colorectal cancer (CRC) is challenged by the heterogeneity of the disease and its variable display of tumor surface markers. Antibody‐Protein L Microparticles (APL‐MPs) leverage the antibody‐binding property of Protein L in a swappable system, enabling easy application to variable targets for personalized therapies.
Saleh Ramezani +11 more
wiley +1 more source
Bispecific antibodies (BsAbs) represent a promising strategy for cancer immunotherapy. Challenges in immunotherapy include inefficient early events in the immune response cycle, such as antigen presentation and T cell priming.
Kun Du, He Huang
doaj +1 more source

